Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by laboratory testing of tumour tissue or cells) with an advanced solid tumour cancer that has stopped responding to standard treatments.
• People whose cancer can be measured using standard imaging criteria known as RECIST v1.1 or RANO-BM (confirm with trial site).
• People who have previously received a treatment that targets a protein called TROP2 — prior use of such therapy is permitted.
• People who are willing to provide stored tumour tissue samples, or to have a new biopsy taken before treatment if stored samples are not available.
• People who may also need to provide tissue samples during treatment, if the trial site's doctors consider this medically safe and appropriate.
• People who are generally well enough to carry out light activity and care for themselves, as measured by a standard health scale (ECOG score of 0 or 1).
• People whose blood counts and organ function meet specific minimum levels — including healthy enough levels of white blood cells, platelets, red blood cells, and liver enzyme readings (confirm exact values with trial site).

Who may not be able to join:

• People whose cancer has spread to the brain or spinal fluid and is currently active or getting worse. Note: people with brain metastases that have been treated and have remained stable for at least one month may still be considered eligible, provided certain conditions are met — such as having finished local brain treatment at least four weeks before starting the study drug, having no new or worsening neurological symptoms, and not needing steroids above a low stable dose or anti-seizure medications for symptom control (confirm with trial site).
• People who are still experiencing side effects from previous cancer treatments that are rated above a mild level (greater than Grade 1), not including hair loss or skin pigmentation changes.
• People who have received other systemic cancer treatments (including hormone-blocking therapies) too recently before the study start date — specifically within five half-lives of the drug or within four weeks, whichever period is shorter.
• People who are currently taking systemic steroid medications at a dose higher than 10 mg of prednisone per day (or an equivalent dose of another steroid), except in specific circumstances related to stable brain metastases as described above.

Important: Always verify eligibility with the trial site directly before applying.